Business Wire | Jul 23, 2020 08:30AM EDT

Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights

Jul. 23, 2020

BRISBANE, Calif.--(BUSINESS WIRE)--Jul. 23, 2020--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Thursday, July 30, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter and six months ended June 30, 2020, and recent operational highlights.

To access the live call by phone, dial (877) 497-1438 (domestic) or (262) 558-6296 (international) and enter the passcode 6195241. To access a live or recorded webcast of the call, please visit the Investor Relations section of the Aimmune Therapeutics website at www.aimmune.com. The recorded webcast will be available for approximately 30 days following the call.

About Aimmune

Aimmune Therapeutics, Inc. is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing treatments for potentially life-threatening food allergies. The Company's Characterized Oral Desensitization ImmunoTherapy (CODIT(tm)) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies. For more information, please visit www.aimmune.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005075/en/

CONTACT: Investors: DeDe Sheel (917) 834-1494 dsheel@aimmune.com

CONTACT: Media: Jodi Sievers (628) 250-6849 Jsievers@aimmune.com